Highest-materiality recent filing
Surrozen reports Q2 2026 results; IND for SZN-8141 planned by Q3 end; PTAB denies Merck petition
Planned IND submission for SZN-8141 in DME by end of Q3 2026; DUET Phase 1b/2a to start by year-end 2026 with initial data in H2 2027.
Elected Mace Rothenberg, M.D. (5,982,651 for, 1,107,751 withheld) and David J. Woodhouse (7,087,293 for, 3,109 withheld) as Class II directors.
Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026
Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.
Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026
Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.
Director Shao-Lee Lin resigns from Surrozen board effective immediately
Shao-Lee Lin, M.D., Ph.D., resigned from the Board on January 26, 2026, effective immediately.
Surrozen Q3 net loss $71.6M, appoints new CFO
Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.
Surrozen's collaboration agreement terminated by TCGFB for convenience, effective Nov 13
TCGFB terminated Collaboration Agreement for convenience; no termination penalties incurred by either party.
Surrozen enters ATM equity offering agreement for up to $50M with TD Cowen
Sales Agreement with TD Securities (USA) LLC to sell up to $50M of common stock at-the-market or in negotiated transactions.
Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP
Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.
Surrozen stockholders elect three Class I directors and ratify Ernst & Young as auditor
Anna Berkenblit, M.D. elected with 1,351,951 for, 503,791 withheld, 453,045 broker non-votes.
Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology
Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.
Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline
Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.
Surrozen raises ~$76.4M in first tranche private placement; appoints Tim Kutzkey to Board
First tranche closed March 26, 2025; gross proceeds ~$76.4M from 6,586,415 Units at $11.60 each.
Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program
Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.
Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413
Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).
Surrozen extends HQ lease through April 2029 with escalating rent, $400K early termination option
Lease term extended 48 months to April 2029; annual base rent starts at $2.3M, rises to $2.6M.
Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M
Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.
Surrozen director Tim Kutzkey resigns from board and committees effective June 30
Tim Kutzkey, Ph.D. resigned as director and from all board committees on June 30, 2024.
Surrozen reports 2024 annual meeting vote results: directors elected, auditor ratified
Three Class III directors elected: Christopher Y. Chai, Mary Haak-Frendscho, and Craig Parker.
Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024
Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.
Surrozen raises $17.5M in private placement with milestone-triggered warrants
Issues 1,089,033 shares at $15.50 and pre-funded warrants for 40,000 shares at $15.4999.
Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.
Surrozen appoints CFO Charles Williams as COO, retains CFO role; salary increased to $465,000
Charles Williams appointed Chief Operating Officer effective Feb 1, 2024, while continuing as CFO.
Surrozen discontinues SZN-1326; SZN-043 Phase 1a complete, data due Q1 2024
SZN-043 Phase 1a enrollment in chronic liver disease and healthy volunteers complete; safety/pharmacodynamic data expected Q1 2024.
Surrozen announces 1-for-15 reverse stock split effective December 13, 2023
Effective Dec 13, 2023, Surrozen effected a 1-for-15 reverse stock split of its common stock.
Surrozen stockholders approve 1-for-15 reverse stock split, effective Dec 13, 2023
Special meeting Dec 7: 16.2M shares for, 784K against, 0.5K abstain on reverse-split amendment.
Surrozen Q3 net loss $10.4M; cash $43.4M; Phase 1a data expected Q1 2024
Net loss $10.4M vs $13.4M prior year; R&D expenses down to $6.1M from $8.6M.
Surrozen amends bylaws to reduce stockholder quorum to one-third voting power
Board amended and restated Bylaws effective October 10, 2023.
Surrozen Q2 net loss $9.4M; cash runway extended into 2025 on prioritization
Net loss of $9.4M improved from $13.9M YoY; cash and securities $53.4M (down from $61.7M in Q1).
CSO Wen-Chen Yeh to step down on July 31, 2023, as part of a planned restructuring and reduction-in-force.
Surrozen gets Nasdaq extension to Jan 2, 2024 to meet $1 bid price
Received Nasdaq notice of additional 180-day period to regain minimum $1.00 bid price compliance.
Surrozen stockholders re-elect three directors and ratify EY as auditor for 2023
Annual meeting held May 18, 2023; 18,247,744 of 30,079,441 shares represented.
Surrozen Q1 net loss widens to $14.3M; cash at $61.7M; SZN-043 and SZN-1326 trials enroll
Net loss of $14.3M vs $7.9M in Q1 2022, driven by $1.2M restructuring charges and higher G&A.
Surrozen appoints Eric Bjerkholt as Class I director and audit committee member
Eric Bjerkholt appointed to board as Class I director effective April 5, 2023.
Surrozen updates pipeline; cash $75.8M, net loss improves; SZN-043 and SZN-1326 timelines
Cash, equivalents and marketable securities $75.8M at Dec 31, 2022, down from $123.5M; runway into H2 2024.
Surrozen reports FY2022 net loss of $36M; cash runway into H2 2024
Net loss for FY2022 was $36.0M vs $54.6M in FY2021; collaboration revenue $12.5M from Boehringer Ingelheim deal.
Surrozen receives Nasdaq notice for non-compliance with $1.00 minimum bid price
Average closing price of common stock fell below $1.00 over 30 consecutive trading days as of Jan 3, 2023.
Surrozen repurchases 5.38M shares and 1.31M warrants from Consonance for $2.7M
Repurchased 5,382,499 common shares and warrants for 1,310,496 shares from Consonance Entities on Dec. 15, 2022.
Surrozen pauses SZN-1326 Phase 1 trial due to liver enzyme elevations; Q3 net loss $13.4M
Voluntarily paused SZN-1326 Phase 1 SAD trial after grade 3 ALT/AST elevations in 3 subjects; transaminases resolved spontaneously.
Surrozen enters $12.5M upfront license deal with Boehringer Ingelheim for Fzd4 bispecific antibodies
Upfront payment of $12.5 million; eligible for up to $586.5M in development, regulatory, and commercial milestones.
Surrozen becomes clinical-stage with Phase 1 starts for SZN-1326 and SZN-043
Initiated Phase 1 trial for SZN-1326 (ulcerative colitis) in May 2022 and for SZN-043 (alcoholic hepatitis) in June 2022.
Surrozen shareholders elect two directors, ratify Ernst & Young as auditor at 2022 annual meeting
Elected Tim Kutzkey and Anna Berkenblit as directors until the 2025 annual meeting.
Surrozen reports Q1 2022 results; Phase 1 trials on track for Q3
Q1 financial results announced; no specific revenue or loss figures in the press release excerpt.
Surrozen reports full-year 2021 net loss of $47.3M; on track for Phase 1 starts in Q3 2022
FY2021 net loss $47.3M vs $20.4M in 2020; R&D expenses $35.5M.
Surrozen enters $50M equity purchase agreement with Lincoln Park Capital Fund
Up to $50M of common stock may be sold to Lincoln Park over 36 months after Commencement.
Expects to initiate Phase 1 clinical trials of SZN-1326 and SZN-043 in Q3 2022.
Surrozen Q3 2021 net loss $14.0M; cash $135.4M post business combination
Cash, cash equivalents and marketable securities $135.4M as of Sept 30, 2021, up from $18.9M at June 30, 2021.
Surrozen completes SPAC merger; PIPE raises $120.2M, shares trade on Nasdaq under SRZN
Business combination closed Aug 11, 2021; CHFW domesticated as Delaware corporation renamed Surrozen, Inc.
Surrozen completes SPAC merger; Nasdaq listing under SRZN/SRZNW on Aug 12
Business combination with Consonance-HFW Acquisition Corp. closed August 11, 2021.
CHFW shareholders approve merger with Surrozen; all proposals pass with >97% support
BCA approved with 9,712,408 votes for, 176,605 against, 56,351 abstentions.
Upon the recommendation of the Nominating and Corporate Governance Committee, on March 26, 2025, Tim Kutzkey, Ph.D., was appointed to serve as a Class I director of the Company’s Board of Directors
On June 30, 2024, Tim Kutzkey, Ph.D. notified Surrozen, Inc. of his resignation as a member of our board of directors and from all committees of the board of directors on which he served, effective as of June 30, 2024.
On February 1, 2024, Surrozen, Inc. appointed Charles Williams, our current Chief Financial Officer, to the concurrent position of Chief Operating Officer, effective as of February 1, 2024.
On July 14, 2023, Surrozen, Inc. and Wen-Chen Yeh, M.D., Ph.D., our Chief Scientific Officer, agreed that in connection with our planned restructuring and reduction-in-force, Dr. Yeh will cease serving as our Chief Scientific Officer and join our Scientific Advisory Board effective as of July 31, 2023.
On April 5, 2023, the board of directors of Surrozen, Inc. appointed Eric Bjerkholt to serve as a Class I director
Max materiality 0.85 · Median 0.65 · Most common event earnings